These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 30651399)

  • 21. Alpelisib to treat breast cancer.
    Copur MS
    Drugs Today (Barc); 2020 Jun; 56(6):357-363. PubMed ID: 32525134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
    Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
    Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer.
    Moein A; Jin JY; Wright MR; Wong H
    Cancer Chemother Pharmacol; 2024 Sep; 94(3):421-436. PubMed ID: 38937298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
    Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
    J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
    Wang S; Liu M; Lian S; Liu N; Zhang G; Zhao Q; Zhang Y; Jian L
    Biomed Res Int; 2020; 2020():7451576. PubMed ID: 33376736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
    Nixon MJ; Formisano L; Mayer IA; Estrada MV; González-Ericsson PI; Isakoff SJ; Forero-Torres A; Won H; Sanders ME; Solit DB; Berger MF; Cantley LC; Winer EP; Arteaga CL; Balko JM
    NPJ Breast Cancer; 2019; 5():31. PubMed ID: 31552290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
    Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
    Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpelisib: A Novel Therapy for Patients With
    Wilhoit T; Patrick JM; May MB
    J Adv Pract Oncol; 2020; 11(7):768-775. PubMed ID: 33575071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
    Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.
    Varkaris A; Fece de la Cruz F; Martin EE; Norden BL; Chevalier N; Kehlmann AM; Leshchiner I; Barnes H; Ehnstrom S; Stavridi AM; Yuan X; Kim JS; Ellis H; Papatheodoridi A; Gunaydin H; Danysh BP; Parida L; Sanidas I; Ji Y; Lau K; Wulf GM; Bardia A; Spring LM; Isakoff SJ; Lennerz JK; Del Vecchio K; Pierce L; Pazolli E; Getz G; Corcoran RB; Juric D
    Cancer Discov; 2024 Feb; 14(2):227-239. PubMed ID: 37916958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
    Martín M; Chan A; Dirix L; O'Shaughnessy J; Hegg R; Manikhas A; Shtivelband M; Krivorotko P; Batista López N; Campone M; Ruiz Borrego M; Khan QJ; Beck JT; Ramos Vázquez M; Urban P; Goteti S; Di Tomaso E; Massacesi C; Delaloge S
    Ann Oncol; 2017 Feb; 28(2):313-320. PubMed ID: 27803006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+
    Pérez-Fidalgo JA; Criscitiello C; Carrasco E; Regan MM; Di Leo A; Ribi K; Adam V; Bedard PL
    Future Oncol; 2022 Jun; 18(19):2339-2349. PubMed ID: 35465733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.
    Welt A; Wiesweg M; Theurer S; Abenhardt W; Groschek M; Müller L; Schröder J; Tewes M; Chiabudini M; Potthoff K; Bankfalvi A; Marschner N; Schuler M; Breitenbücher F
    Cancer Med; 2020 Jul; 9(13):4527-4539. PubMed ID: 32352244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in
    Pascual J; Lim JSJ; Macpherson IR; Armstrong AC; Ring A; Okines AFC; Cutts RJ; Herrera-Abreu MT; Garcia-Murillas I; Pearson A; Hrebien S; Gevensleben H; Proszek PZ; Hubank M; Hills M; King J; Parmar M; Prout T; Finneran L; Malia J; Swales KE; Ruddle R; Raynaud FI; Turner A; Hall E; Yap TA; Lopez JS; Turner NC
    Cancer Discov; 2021 Jan; 11(1):92-107. PubMed ID: 32958578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
    Majewski IJ; Nuciforo P; Mittempergher L; Bosma AJ; Eidtmann H; Holmes E; Sotiriou C; Fumagalli D; Jimenez J; Aura C; Prudkin L; Díaz-Delgado MC; de la Peña L; Loi S; Ellis C; Schultz N; de Azambuja E; Harbeck N; Piccart-Gebhart M; Bernards R; Baselga J
    J Clin Oncol; 2015 Apr; 33(12):1334-9. PubMed ID: 25559818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Krop IE; Mayer IA; Ganju V; Dickler M; Johnston S; Morales S; Yardley DA; Melichar B; Forero-Torres A; Lee SC; de Boer R; Petrakova K; Vallentin S; Perez EA; Piccart M; Ellis M; Winer E; Gendreau S; Derynck M; Lackner M; Levy G; Qiu J; He J; Schmid P
    Lancet Oncol; 2016 Jun; 17(6):811-821. PubMed ID: 27155741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefits versus risk profile of buparlisib for the treatment of breast cancer.
    Patsouris A; Augereau P; Frenel JS; Robert M; Gourmelon C; Bourbouloux E; Berton-Rigaud D; Chevalier LM; Campone M
    Expert Opin Drug Saf; 2019 Jul; 18(7):553-562. PubMed ID: 31159599
    [No Abstract]   [Full Text] [Related]  

  • 38. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
    Kataoka Y; Mukohara T; Shimada H; Saijo N; Hirai M; Minami H
    Ann Oncol; 2010 Feb; 21(2):255-262. PubMed ID: 19633047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
    Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
    Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of PI3K inhibitors in advanced breast cancer.
    Verret B; Cortes J; Bachelot T; Andre F; Arnedos M
    Ann Oncol; 2019 Dec; 30(Suppl_10):x12-x20. PubMed ID: 31859349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.